Moderna's Dual Vaccine Breakthrough in Europe

Moderna (MRNA.O) received European regulatory approval for its dual flu-COVID vaccine on Tuesday, establishing it as the first messenger RNA immunization to defend against both respiratory diseases in adults 50 years and above.

This regulatory achievement offers Moderna a promising new income source as the biotech firm works to expand beyond its coronavirus vaccine portfolio, which reached record revenues of $18.4 billion in 2022 before experiencing a substantial downturn.

Key Takeaways

First combined flu-COVID mRNA vaccine approved in Europe
Targets adults 50+ with single-shot convenience
US approval remains uncertain amid regulatory scrutiny

Market reaction & context

The European Medicines Agency’s Committee for Medicinal Products for Human Use endorsed marketing authorization for mCombriax, enabling Moderna to challenge existing flu vaccines from Sanofi and GSK ¹. Trial results from 8,000 participants demonstrated the dual vaccine generated immune responses that were statistically non-inferior to current individual vaccines ².

Moderna’s vaccine division has encountered challenges as coronavirus demand stabilized, with respiratory vaccine revenues dropping 29% year-over-year in Q3 2025. The combination strategy could assist the company in recovering market position during seasonal vaccination periods.

Detailed analysis

The mCombriax formulation includes messenger RNA sequences for producing proteins present on SARS-CoV-2 and three seasonal flu virus strains: H1N1, H3N2, and influenza B Victoria lineage ¹. Similar to current COVID and influenza vaccines, the formula will receive periodic updates to correspond with prevalent viral variants.

European health statistics referenced by regulators indicated over 281 million COVID-19 cases documented in the region through February 2026, while seasonal flu results in up to 50 million symptomatic infections yearly throughout the European Economic Area ¹. The predominant adverse effects encompass injection site discomfort, tiredness, muscle aches, and fever, with symptoms generally persisting three days ¹.

Outlook & management quote

“The CHMP’s positive opinion represents an important milestone for respiratory virus vaccination and for Moderna,” CEO Stephane Bancel said in a statement ³. “Combination vaccines have the potential to simplify vaccination and support improved health outcomes.”

The European Commission must now validate the recommendation before the vaccine becomes available for distribution across EU member nations. National health authorities will determine which vaccines to implement and establish guidance regarding target demographics according to their particular epidemiological circumstances ¹.

US regulatory uncertainty

Moderna’s route to US authorization remains complex after the FDA initially declined to evaluate the application in 2024, subsequently changing direction following industry advocacy ⁴. The Trump administration’s selection of vaccine skeptics for critical health roles has introduced further regulatory ambiguity for mRNA platforms.

The company had previously retracted its US filing after the FDA requested supplementary data, then resubmitted the application with a confirmed August 2026 action deadline ⁵. This regulatory disparity between Europe and America underscores different methodologies for assessing combination vaccines.

Conclusion

European clearance of mCombriax represents a notable regulatory achievement for combination respiratory immunizations, potentially streamlining seasonal vaccination programs. Nevertheless, Moderna’s commercial performance will hinge on pricing discussions with individual EU countries and ultimate US market entry.

The vaccine constitutes Moderna’s fourth commercialized product in Europe, broadening its offerings beyond COVID-19 as the organization aims to develop a more comprehensive infectious disease platform.

Not investment advice. For informational purposes only.